The lawsuits claim Teva struck deals to settle patent suits with Gilead that delayed the introduction of a generic form of Viread until December 2017 and generic forms of Truvada and Atripla until ...

The first cross-class fixed-dose combination, Atripla, was developed by Gilead and Bristol–Myers Squibb (BMS), and launched in 2006 in the United States. This once-daily pill containing an NNRTI ...

The company gained widespread recognition for its development of antiretroviral drugs for the treatment of HIV/AIDS, ...

News, January 29, 2008 International Approvals: Humira, Atripla, Januvia Europe has approved a new indication for adalimumab subcutaneous injection (Humira) and efavirenz/emtricitabine/tenofovir ...

As a former trial attorney with more than a decade of litigation experience, Jamie L. Pfeiffer writes trustworthy, engaging and informative content for law firm websites, legal publications and ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...

(Nasdaq: GILD) announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of ...

Tenofovir is available as tablets (300mg) and in fixed-dose combinations with emtricitabine (Truvada ®) and with emtricitabine plus efavirenz (Atripla ®); the latter combination was recently ...

Analyst Salveen Richter of Goldman Sachs maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of $73.00. Salveen Richter has given his Hold rating due to a ...

Emily Field, an analyst from Barclays, maintained the Hold rating on Gilead Sciences (GILD – Research Report). The associated price ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...